Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled "Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells" (U.S. Application No. 17/931,868).

Once formally issued, the patent will extend Creative Medical’s intellectual property protection around its proprietary MyeloCelz™ platform, a cell-free exosome technology derived from stem-cell-programmed myeloid cells that is designed to induce antigen-specific immune tolerance and suppress the autoimmune destruction of insulin-producing pancreatic beta cells that underlies Type 1 diabetes (T1D). The allowed claims cover the use of these exosomes alone, or in combination with other tolerance-promoting agents such as antibodies, cellular therapies and small molecules, to selectively shut down the immune cells responsible for attacking the pancreas while preserving the immune system’s ability to fight infection and disease.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.